We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

419 hedge funds and large institutions have $9.23B invested in Neurocrine Biosciences in 2021 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 161 increasing their positions, 127 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more call options, than puts

Call options by funds: $69.4M | Put options by funds: $52.1M

28% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 60

27% more repeat investments, than reductions

Existing positions increased: 161 | Existing positions reduced: 127

7% more capital invested

Capital invested by funds: $8.6B → $9.23B (+$636M)

5.45% more ownership

Funds ownership: 95.84% → 101.28% (+5.4%)

3% more funds holding

Funds holding: 405 → 419 (+14)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
419
Holders Change
+14
Holders Change %
+3.46%
% of All Funds
7.36%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
77
Increased
161
Reduced
127
Closed
60
Calls
$69.4M
Puts
$52.1M
Net Calls
+$17.2M
Net Calls Change
+$93.8M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$419M
2
PHS
PFM Health Sciences
California
+$111M
3
State Street
State Street
Massachusetts
+$82.8M
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$79.7M
5
DM
Deerfield Management
New York
+$76M

Top Sellers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
-$193M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$132M
3
PA
Perceptive Advisors
New York
-$100M
4
RSCM
Rock Springs Capital Management
Maryland
-$58.7M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$52.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
PL
426
Polianta Ltd
Jersey
– -$1.29M -13,500 Closed
AC
427
Athanor Capital
New York
– -$1.15M -12,022 Closed
BC
428
Blackcrane Capital
Washington
– -$1.1M -11,499 Closed
CIS
429
Capital International Sarl
California
– -$856K -8,934 Closed
PI
430
PEAK6 Investments
Illinois
– -$872K -8,319 Closed
PHK
431
Point72 Hong Kong
Hong Kong
– -$777K -8,107 Closed
AIL
432
AGF Investments LLC
Ontario, Canada
– -$744K -7,766 Closed
TI
433
Trexquant Investment
Connecticut
– -$698K -7,283 Closed
TLP
434
Tri Locum Partners
New York
– -$688K -7,178 Closed
ECM
435
ExodusPoint Capital Management
New York
– -$669K -6,983 Closed
DF
436
Donoghue Forlines
Massachusetts
– -$643K -6,713 Closed
Jacobs Levy Equity Management
437
Jacobs Levy Equity Management
New Jersey
– -$605K -6,308 Closed
Bank of Nova Scotia
438
Bank of Nova Scotia
Ontario, Canada
– -$554K -5,780 Closed
OCM
439
Ovata Capital Management
Hong Kong
– -$479K -5,000 Closed
AII
440
AGF Investments Inc
Ontario, Canada
– -$405K -4,226 Closed
NAM
441
NorthCoast Asset Management
Connecticut
– -$402K -4,195 Closed
N
442
Natixis
France
– -$386K -4,030 Closed
B
443
Bailard
California
– -$374K -3,900 Closed
HF
444
HRT Financial
New York
– -$331K -3,456 Closed
CCM
445
Copernicus Capital Management
California
– -$296K -3,089 Closed
FHB
446
First Hawaiian Bank
Hawaii
– -$295K -3,078 Closed
JGGDR
447
JGP Global Gestao de Recursos
Brazil
– -$272K -2,841 Closed
ACM
448
Adalta Capital Management
New York
– -$251K -2,615 Closed
WAS
449
WESPAC Advisors SoCal
California
– -$236K -2,465 Closed
VWM
450
Vigilare Wealth Management
Arizona
– -$208K -2,170 Closed
16 17
18
19 20

NBIX Hedge Fund Activity: Q1 2021 in Review

419 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2021, worth a combined $9.23B — up 7.4% from $8.6B a quarter earlier.

Buyers outnumbered sellers: 77 funds opened new NBIX positions and 60 closed out — a net gain of 17 holders — while 161 added to existing stakes and 127 trimmed.

The largest buyer was BlackRock, adding an estimated $419M. The largest seller was Capital International Investors, cutting an estimated $193M.

  • 419 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2021, up from 405 in Q4 2020.
  • Funds reported $9.23B of Neurocrine Biosciences stock for Q1 2021, up 7.4% quarter-over-quarter.
  • 77 funds opened new Neurocrine Biosciences positions in Q1 2021 and 60 closed out, a net change of +17 holders.
  • The largest Neurocrine Biosciences buyer in Q1 2021 was BlackRock, an estimated $419M added.
  • The largest Neurocrine Biosciences seller in Q1 2021 was Capital International Investors, an estimated $193M sold.

Based on aggregated 13F filings for Q1 2021.